US Patent

US8545878 — Capsules containing high doses of levodopa for pulmonary use

Formulation · Assigned to Civitas Therapeutics Inc · Expires 2032-11-16 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a capsule containing a high-dose levodopa inhalable powder composition with specific ingredients and properties.

USPTO Abstract

The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.

Drugs covered by this patent

Patent Metadata

Patent number
US8545878
Jurisdiction
US
Classification
Formulation
Expires
2032-11-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Civitas Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.